Search results for

The top petitioners, patent owners, law firms and attorneys in Patent Trial and Appeal Board petitions filed in 2016 have been revealed from Docket Navigator data. Apple only just hung onto its top petitioner status

(UPDATED FEBRUARY 8) Last month’s granting of an Amgen permanent injunction motion in its cholesterol drug patent dispute with Sanofi and Regeneron would “give another arrow in the quiver” of those seeking permanent injunctions in similar cases, if it is upheld on appeal

Natalie Rahhal analyses the issues at stake when the US Supreme Court hears the biosimilars dispute between Sandoz and Amgen later this year

The Patent Trial and Appeal Board has dismissed three inter partes review petitions filed by Covidien because the University of Florida Research Foundation is entitled to an Eleventh Amendment sovereign immunity defence

How Neil Gorsuch's appointment to the US Supreme Court would affect intellectual property, the invalidation of four of Teva’s Copaxone patents, Tim Cook’s sofa analogy about Qualcomm, Apple’s IPR strategy and a comprehensive overview of NFL-related litigation were in the recent intellectual property news

PhRMA, ABA and AIPLA have submitted comments to the USPTO, and IPO has passed a resolution, all urging legislative changes to Section 101

A recent decision from the Federal Circuit recognises a privilege between non-attorneys patent-agents and their clients under certain conditions. Philippe Signore reviews the limits of this patent agent privilege, as well as those of the attorney-client privilege, within the context of the discovery phase of a US litigation

With the steadily increasing role of technology in society, many companies seek to promote their innovative power more widely, as an integral part of their overall brand image. Zeeger Vink explores how IP rights can support such a strategy

For many patent applicants, the primary value of the PCT is as a delaying tactic. But, say David Grant, Thomas Prock and Ed Round, it can also be used strategically

Vietnam's IP enforcement system has seen great improvements over the past few years. In particular, the Inspectorate of the Ministry of Science and Technology (MOST) has handled many complex disputes in the pharmaceutical sector related to patent infringement, unfair competition and trade mark infringement. Rights holders have generally been quite pleased with the decisions reached by MOST, as well as the expert opinions provided in various cases by the National Office of Intellectual Property (NOIP) and the Vietnam Intellectual Property Research Institute (VIPRI), which are often a precursor to a MOST administrative enforcement action. Nevertheless, with a few tweaks when Vietnam amends its Law on Intellectual Property this year, the system can be improved even further to help better protect IP in the pharma sector. Below are a few suggestions for improvement.